Here are the 10-K annual reports from CalciMedica, Inc. (CALC) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow CALC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CALC filings page.
CalciMedica, Inc. filed an amendment to its annual report to add detailed Part III disclosures on directors, executive officers, compensation, ownership and related-party transactions. The Board has seven members, a majority of whom are independent under Nasdaq rules, with key committees fully composed of independent directors.
The filing outlines 2025 pay for three named executives, including total compensation of $895,410 for CEO A. Rachel Leheny, $763,315 for Chief Medical Officer Sudarshan Hebbar and $703,558 for Chief Business Officer Eric Roberts, largely driven by stock option awards. It also lists extensive outstanding equity awards and change-in-control severance protections.
As of June 30, 2025, non-affiliates held common stock with an aggregate market value of about $15.7 million, and 15,743,916 shares were outstanding as of February 25, 2026. The amendment details equity plan capacity, a three-year clawback policy tied to restatements, related-party consulting and financing arrangements, and a $20.4 million 2024 private placement, including participation by major holders and insiders.
CalciMedica, Inc. is a clinical-stage biopharmaceutical company developing calcium release-activated calcium (CRAC) channel inhibitors, led by its intravenous candidate Auxora for acute pancreatitis and other critical inflammatory conditions. The company has never generated product revenue and discloses a history of net losses with substantial doubt about its ability to continue as a going concern without significant additional capital.
Auxora has shown encouraging Phase 2 data in acute pancreatitis, severe COVID-19 pneumonia, and pediatric asparaginase-induced pancreatic toxicity, and CalciMedica plans to finalize a pivotal program design in acute pancreatitis in the first half of 2026. A Phase 2 trial in acute kidney injury with acute hypoxemic respiratory failure (KOURAGE) was discontinued in January 2026 after a mortality imbalance, though independent reviewers did not find drug-related toxicity, and the company will discuss future development with the FDA.
CalciMedica is also advancing CM5480, an Orai1-selective CRAC inhibitor, toward an anticipated 2027 IND for pulmonary arterial hypertension and is exploring oral CRAC inhibitors in chronic inflammatory and immunologic diseases. It relies on third-party manufacturers, faces intense competition in inflammation and critical care, and highlights extensive scientific and development risks alongside potential opportunities for strategic partnerships.